BlackRock Inc. Has $3.31 Billion Position in Danaher Corporation (DHR)
BlackRock Inc. lifted its position in Danaher Corporation (NYSE:DHR) by 3.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 39,201,798 shares of the conglomerate’s stock after acquiring an additional 1,233,876 shares during the period. BlackRock Inc. owned approximately 5.64% of Danaher Corporation worth $3,308,239,000 at the end of the most recent quarter.
Several other large investors have also recently made changes to their positions in the stock. Vanguard Group Inc. raised its position in shares of Danaher Corporation by 3.9% in the 1st quarter. Vanguard Group Inc. now owns 40,967,631 shares of the conglomerate’s stock valued at $3,503,962,000 after acquiring an additional 1,530,015 shares during the period. FMR LLC raised its holdings in Danaher Corporation by 0.3% during the 1st quarter. FMR LLC now owns 19,441,167 shares of the conglomerate’s stock worth $1,662,803,000 after buying an additional 53,429 shares during the period. Geode Capital Management LLC raised its holdings in Danaher Corporation by 6.0% during the 1st quarter. Geode Capital Management LLC now owns 5,815,659 shares of the conglomerate’s stock worth $496,687,000 after buying an additional 329,458 shares during the period. Flossbach Von Storch AG raised its holdings in Danaher Corporation by 44.7% during the 2nd quarter. Flossbach Von Storch AG now owns 5,782,019 shares of the conglomerate’s stock worth $487,945,000 after buying an additional 1,785,810 shares during the period. Finally, Dimensional Fund Advisors LP raised its holdings in Danaher Corporation by 17.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 4,661,469 shares of the conglomerate’s stock worth $398,696,000 after buying an additional 703,224 shares during the period. Institutional investors and hedge funds own 75.66% of the company’s stock.
In other news, insider Thomas Patrick Joyce, Jr. sold 9,772 shares of the stock in a transaction on Monday, July 31st. The stock was sold at an average price of $81.78, for a total transaction of $799,154.16. Following the completion of the transaction, the insider now owns 155,520 shares in the company, valued at approximately $12,718,425.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider William King sold 43,688 shares of the stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $82.86, for a total value of $3,619,987.68. Following the transaction, the insider now owns 45,748 shares of the company’s stock, valued at approximately $3,790,679.28. The disclosure for this sale can be found here. Insiders have sold a total of 71,496 shares of company stock valued at $5,916,223 in the last quarter. 12.20% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION WARNING: This story was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://www.thecerbatgem.com/2017/10/18/blackrock-inc-has-3-31-billion-position-in-danaher-corporation-dhr.html.
Several analysts have commented on the stock. Zacks Investment Research downgraded shares of Danaher Corporation from a “buy” rating to a “hold” rating in a report on Thursday, July 27th. BidaskClub downgraded shares of Danaher Corporation from a “hold” rating to a “sell” rating in a report on Tuesday, July 25th. Citigroup Inc. set a $96.00 target price on shares of Danaher Corporation and gave the stock a “buy” rating in a report on Friday, July 21st. Royal Bank Of Canada restated a “hold” rating and set a $88.00 target price on shares of Danaher Corporation in a report on Wednesday, July 12th. Finally, Cowen and Company restated a “buy” rating and set a $90.00 target price on shares of Danaher Corporation in a report on Wednesday, October 4th. One analyst has rated the stock with a sell rating, four have issued a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. Danaher Corporation has an average rating of “Buy” and a consensus price target of $92.62.
Shares of Danaher Corporation (NYSE:DHR) opened at 85.26 on Wednesday. The stock’s 50 day moving average price is $85.95 and its 200-day moving average price is $84.19. The firm has a market cap of $59.23 billion, a P/E ratio of 27.21 and a beta of 1.03. Danaher Corporation has a 12-month low of $75.71 and a 12-month high of $88.62.
Danaher Corporation (NYSE:DHR) last posted its quarterly earnings results on Thursday, July 20th. The conglomerate reported $0.99 earnings per share for the quarter, topping the consensus estimate of $0.97 by $0.02. The company had revenue of $4.51 billion during the quarter, compared to the consensus estimate of $4.50 billion. Danaher Corporation had a return on equity of 11.15% and a net margin of 12.63%. The firm’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.90 EPS. On average, analysts predict that Danaher Corporation will post $3.96 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Friday, September 29th will be paid a dividend of $0.14 per share. The ex-dividend date of this dividend is Thursday, September 28th. This represents a $0.56 annualized dividend and a dividend yield of 0.66%. Danaher Corporation’s payout ratio is 17.83%.
Danaher Corporation Profile
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR).
Receive News & Stock Ratings for Danaher Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Corporation and related stocks with our FREE daily email newsletter.